Incyte (INCY) Total Current Liabilities (2010 - 2026)
Incyte (INCY) posted Total Current Liabilities of $1.5 billion for Q1 2026, down 1.68% on a QoQ basis from $1.5 billion in Q4 2025, and down 13.41% year-over-year from $1.7 billion in Q1 2025.
Incyte (INCY) Total Current Liabilities (2010 - 2026) Analysis & Trends
Incyte's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- Quarterly Total Current Liabilities fell 13.41% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 13.41% YoY) and the FY2025 annual result came in at $1.5 billion, down 7.72% from the prior year.
- Total Current Liabilities was $1.5 billion for Q1 2026 at Incyte, down from $1.5 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $1.7 billion in Q1 2025 and bottomed at $886.2 million in Q1 2022.
- A 5-year average of $1.3 billion and a median of $1.3 billion in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 42.04% — and 2026, when it fell 13.41%.
- Incyte's Total Current Liabilities stood at $1.2 billion in 2022, then climbed by 7.2% to $1.2 billion in 2023, then surged by 32.37% to $1.6 billion in 2024, then decreased by 7.72% to $1.5 billion in 2025, then retreated by 1.68% to $1.5 billion in 2026.
- Business Quant data shows INCY's Total Current Liabilities at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 289.60 Mn |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn | 1.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.49 Bn |
| Dec 31, 2025 | 1.52 Bn |
| Sep 30, 2025 | 1.34 Bn |
| Jun 30, 2025 | 1.28 Bn |
| Mar 31, 2025 | 1.72 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Sep 30, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.34 Bn |
| Mar 31, 2024 | 1.40 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.12 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.01 Bn |
| Dec 31, 2022 | 1.16 Bn |
| Sep 30, 2022 | 1.01 Bn |
| Jun 30, 2022 | 926.67 Mn |
| Mar 31, 2022 | 886.16 Mn |
| Dec 31, 2021 | 854.31 Mn |
| Sep 30, 2021 | 742.71 Mn |
| Jun 30, 2021 | 660.32 Mn |